Albireo Stock Today

ALBO
 Stock
  

USD 22.11  0.10  0.45%   

Market Performance
7 of 100
Odds Of Distress
Over 84
Albireo Pharma is selling for 22.11 as of the 26th of November 2022. This is a 0.45% increase since the beginning of the trading day. The stock's open price was 22.01. Albireo Pharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Albireo Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of June 2021 and ending today, the 26th of November 2022. Click here to learn more.
CUSIP
09064M105
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of May 2007
Category
Healthcare
Classification
Health Care
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. The company has 19.28 M outstanding shares of which 1.76 M shares are presently shorted by private and institutional investors with about 2.99 trading days to cover. More on Albireo Pharma

Moving together with Albireo Pharma

+0.66SGMLSigma Lithium Corp Buyout TrendPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Albireo Pharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Albireo Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Albireo Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Albireo Pharma has very high historical volatility over the last 90 days
Albireo Pharma has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 51.22 M. Net Loss for the year was (36.26 M) with profit before overhead, payroll, taxes, and interest of 39.22 M.
Albireo Pharma currently holds about 180.97 M in cash with (113.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.23.
Albireo Pharma has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Albireo Pharma Third Quarter 2022 Earnings Revenues Beat Expectations, EPS Lags - Simply Wall St
President CEO, DirectorRonald Cooper
Average Analyst Recommendation
Analysts covering Albireo Pharma report their recommendations after researching Albireo Pharma's financial statements, talking to executives and customers, or listening in on Albireo Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Albireo Pharma. The Albireo consensus assessment is calculated by taking the average forecast from all of the analysts covering Albireo Pharma.
Strong Buy5 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Albireo Pharma based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Albireo Pharma financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted20.7 M19.2 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares20.7 M19.2 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities48.9 M45.3 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities136.4 M126.4 M
Significantly Up
Increasing
Slightly volatile
Gross Margin86.4886.99
Slightly Down
Decreasing
Slightly volatile
Total Debt9.6 M10 M
Sufficiently Down
Increasing
Slightly volatile
Asset Turnover0.130.1381
Notably Down
Decreasing
Slightly volatile
Current Assets290.2 M268.9 M
Significantly Up
Increasing
Slightly volatile
Total Assets325.9 M302.1 M
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Albireo Pharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Albireo Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Albireo Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Albireo Pharma's financial leverage. It provides some insight into what part of Albireo Pharma's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Albireo Pharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Albireo Pharma deploys its capital and how much of that capital is borrowed.
Liquidity
Albireo Pharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 20.41 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. Albireo Pharma has a current ratio of 4.4, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Albireo Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Albireo Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Albireo Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Albireo to invest in growth at high rates of return. When we think about Albireo Pharma's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(110.39 Million)
Albireo Pharma (ALBO) is traded on NASDAQ Exchange in USA and employs 130 people. The company currently falls under 'Small-Cap' category with current market capitalization of 426.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Albireo Pharma's market, we take the total number of its shares issued and multiply it by Albireo Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Albireo Pharma conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 19.28 M outstanding shares of which 1.76 M shares are presently shorted by private and institutional investors with about 2.99 trading days to cover. Albireo Pharma currently holds about 180.97 M in cash with (113.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.23.
Check Albireo Pharma Probability Of Bankruptcy
Ownership
Albireo Pharma holds a total of nineteen million two hundred eighty thousand outstanding shares. The majority of Albireo Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Albireo Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Albireo Pharma. Please pay attention to any change in the institutional holdings of Albireo Pharma as this could imply that something significant has changed or about to change at the company. Also note that nearly nine hundred sixty-four thousand invesors are currently shorting Albireo Pharma expressing very little confidence in its future performance.

Ownership Allocation (%)

Check Albireo Ownership Details

Albireo Stock Price Odds Analysis

Proceeding from a normal probability distribution, the odds of Albireo Pharma jumping above the current price in 90 days from now is about 12.29%. The Albireo Pharma probability density function shows the probability of Albireo Pharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.1457. This suggests Albireo Pharma market returns are very sensitive to returns on the market. As the market goes up or down, Albireo Pharma is expected to follow. Additionally, the company has an alpha of 0.2641, implying that it can generate a 0.26 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 22.11HorizonTargetOdds Above 22.11
87.63%90 days
 22.11 
12.29%
Based on a normal probability distribution, the odds of Albireo Pharma to move above the current price in 90 days from now is about 12.29 (This Albireo Pharma probability density function shows the probability of Albireo Stock to fall within a particular range of prices over 90 days) .

Albireo Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Albireo Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Albireo Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Albireo Pharma's value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K97 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.9 K146 K
Wolverine Trading LlcCall Options17.3 K307 K
View Albireo Pharma Diagnostics

Albireo Pharma Historical Income Statement

Albireo Pharma Income Statement is one of the three primary financial statements used for reporting Albireo's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Albireo Pharma revenue and expense. Albireo Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Albireo Pharma Selling General and Administrative Expense is quite stable at the moment as compared to the past year. The company's current value of Selling General and Administrative Expense is estimated at 75.06 Million. Weighted Average Shares is expected to rise to about 20.7 M this year, although the value of Consolidated Income will most likely fall to (36.7 M). View More Fundamentals

Albireo Stock Against Markets

Picking the right benchmark for Albireo Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Albireo Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Albireo Pharma is critical whether you are bullish or bearish towards Albireo Pharma at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Volatility Analysis Now

   

Volatility Analysis

Get historical volatility and risk analysis based on latest market data
All  Next Launch Module

Albireo Pharma Corporate Directors

Albireo Pharma corporate directors refer to members of an Albireo Pharma board of directors. The board of directors generally takes responsibility for the Albireo Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Albireo Pharma's board members must vote for the resolution. The Albireo Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Brian Pereira - Independent DirectorProfile
Davey Scoon - DirectorProfile
Stephanie Okey - DirectorProfile
Roger Jeffs - DirectorProfile

Invested in Albireo Pharma?

The danger of trading Albireo Pharma is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Albireo Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Albireo Pharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Albireo Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
465.9 M
Quarterly Revenue Growth YOY
1.68
Return On Assets
(0.25) 
Return On Equity
(0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.